


Cobryketone Derived from Vitamin B₁₂ via Palladium-Catalyzed Cleavage of the sp³–sp³ Carbon–Carbon Bond

Sylwester Kurcoń, Keith ó Proinsias, and Dorota Gryko*

Institute of Organic Chemistry PAS, Kasprzaka 44/52, 01-224 Warsaw, Poland

S Supporting Information



ABSTRACT: Heptamethyl cobyrinate was transformed into hexamethyl 8-*nor*-cobyrinate. The crucial step involved the synthesis of new, vitamin B₁₂ derived cobryketone *via* palladium-catalyzed cleavage of the sp³–sp³ carbon–carbon bond with the liberation of the ketone. The replacement of sp³ carbon atom with sp² (C=O) at the 8-position produces a bathochromic shift of all absorption bands and makes α and β bands equal as a consequence of the expansion of the existing conjugated system of double bonds.

INTRODUCTION

The total synthesis of vitamin B₁₂ reported by Eschenmoser/Woodward is one of the most spectacular and most complex in the history of organic chemistry (Figure 1).¹ As a consequence, its derivatives have been exclusively obtained *via* modifications of the natural compound.² They have been studied as cyanide detoxifying agents,³ sensors for the optical detection of cyanide ion,⁴ oral delivery vehicles for therapeutic agents,^{5,6} artificial

and model enzymes, and catalysts for various organic reactions.^{2b} These applications require efficient methods for the synthesis of such compounds. The most valuable are, of course, selective modifications relying on the transformation of the peripheral functional groups or reactions at the cobalt center.² For example, alkylation of the cobalt atom with alkyl/acyl halides, epoxides, *O*-sulfonates *etc.*⁷ Treatment of vitamin B₁₂ with a carbonyl group equivalent (CDI, 1,1'-carbonyldiimidazole or CDT, 1,1'-carbonyl-di(1,2,4-triazole)) followed by addition of nucleophiles gives carbamates/carbonates at 5'-hydroxyl group on the ribose moiety.^{6b–d} This methodology was used for coupling of therapeutic agents to vitamin B₁₂ due to its specific uptake pathway.⁵ Complete methanolysis of peripheral amides furnished hydrophobic heptamethyl cobyrinate,⁸ but for further functionalization *c*-monoacid hexamethyl cobyrinate obtained from the reductive ring opening of *c*-lactone is the most useful.⁹ Recently, we have shown that *c*-lactone allows selective modifications not only at the *c*- but also at the *d*-position.¹⁰ It is also possible to modify the structure at the *d*-position without interfering with position *c* using (CN)₂Cby(OMe)₇-10NH₂ as a starting material.¹¹ It was found that these compounds activate guanylyl cyclase (sGC) better than cobinamide, suggesting that modifications to vitamin B₁₂ may provide an attractive approach toward more effective regulators.¹⁰ As a part of our ongoing project we




Figure 1. Conjugated system of double bonds in vitamin B₁₂.

Received: March 5, 2013

Published: April 1, 2013

wanted to determine structural features of cobyrinic acid derivatives crucial for enzyme binding; for example, removal of one or two side chains may give rise to the precise orientation of the bound molecule.

There are few reports describing alterations to the corrin core. One of the rare examples is the green corrinoid reported by Brown et al.¹² Treatment of vitamin B₁₂ derivative possessing a urethane moiety at the 8-position with KOH furnishes the modified corrinoid with up to 40% yield. The B pyrrole ring aromatizes by the loss of the $-\text{CH}_2\text{NH}_2$ substituent from position 7 and loss of hydrogen from position 8. Recently, Kräutler et al. have shown that partial degradation of cobalamin in the presence of sodium bicarbonate leads to a blue corrinoid in 6% yield.¹³ Similarly, pyrolysis of heptamethyl cobyrinate furnishes deep-green pyrocobester with perturbed chromophore in 34% yield.¹⁴ Dicyano-18,19-didehydrocobyrinic acid hexamethylester *c*-amide obtained by Koppenhagen also exhibits substantial bathochromic shifts of the absorption bands.¹⁵ On the other hand, cleavage of the corrin macrocycle leads to yellow corrinoids, which commonly arise in cobalamin chemistry.¹⁶ For example, oxidation of heptamethyl cobyrinate with oxygen in the presence of ascorbic acid gives a disrupted corrinoid in 30% yield.^{16a,b} It possesses hydroxyl groups at positions 5 and 6 with the latter being involved in lactone formation. The breakage of the conjugation between C5 and C6 was reported by Sheldrick, who isolated a yellow lactam with the amine group attached to C6 position.^{16a,h}

RESULTS AND DISCUSSION

We envisaged that the system of conjugated double bonds in the corrin ring could be expanded *via* selective cleavage of one or more of the peripheral propionate or acetate side chains under oxidative conditions. Our first attempted oxidation of $(\text{CN})_2\text{Cby(III)(OMe)}_7$ **1a** with KMnO_4 gave a complex mixture of products with no detectable color change (Scheme 1; Table 1, entry 1).

Since it is well-known that C–C bond cleavage can occur *via* transition-metal-catalyzed reactions, we considered them as an option.¹⁷ The first example of ruthenium-catalyzed deallylation

Scheme 1. Cobryketone 2 Synthesis




Table 1. Oxidation of Heptamethyl Cobyrinate **1a**^a

entry	reagent	time [h]	temp [°C]	result
1 ^b	KMnO_4	5	40	c. m. ^c
2	$\text{Pd}(\text{OAc})_2$	24	50	traces of 2a
3	$\text{RuCl}_2\text{PPh}_3$	24	50	n. d. ^d

^aReaction conditions: $(\text{CN})_2\text{Cby(III)(OMe)}_7$ **1a** (4.6 μmol), reagent (20% mol), DMF conc 0.07 M. ^b25 equiv of reagent, pyridine instead of DMF used, conc 0.02 M. ^cComplicated mixture. ^dNot detected.

of tertiary homoallyl alcohols *via* selective cleavage of C–C bond leading to a ketone was reported by Kondo and Mitsudo et al.¹⁸ It was also found that aryl–aryl coupling can be achieved *via* C–C bond cleavage.¹⁹ For example, α,α -disubstituted arylmethanols react with aryl halides in the presence of palladium acetate with the liberation of ketones to give biaryls.¹⁹ Hence, heptamethyl cobyrinate **1a** was treated with either Pd or Ru complexes in DMF. Interestingly, in our case the reaction in the presence of Pd changed color and furnished traces of a blue-green product, while ruthenium-catalyzed reaction gave no conversion. The structure of blue-green compound **2a** was elucidated on the basis of MS, UV–vis, elemental analysis, and ¹³C/¹H NMR techniques and assigned as cobryketone **2a**.

Subsequently, the synthesis of unique vitamin B₁₂ derivative **2a** was optimized. Continuing from the synthesis using $\text{Pd}(\text{OAc})_2$, the possibility that cobryketone **2a** formation proceeded in the absence of an oxidant was very unlikely. Indeed a reaction conducted under rigorously dry and deoxygenated conditions led to the recovery of starting material **1a** (Table 2, entry 1).

Table 2. Screening of Reaction Conditions^a

entry	oxidant	phosphine	additive	time [h]	yield of 2a [%]
1 ^b				24	n. d. ^d
2			H_2O	4.5	n. d. ^d
3	O_2			3	14
4 ^c	O_2	PPh_3	H_2O	4.5	32
5	O_2	PPh_3		3	24
6	O_2	PPh_3	H_2O	4.5	26
7	O_2	DavePhos	H_2O	4.5	22
8	O_2	<i>t</i> -Bu ₃ P	H_2O	4.5	19
9	O_2	Cy_3P	H_2O	4.5	trace
10	O_2	PPh_3	H_2O , KOAc	4.5	21
11	O_2	PPh_3	H_2O , CsOAc	4.5	10

^aReaction conditions: $(\text{CN})_2\text{Cby(III)(OMe)}_7$ **1a** (14 μmol), $\text{Pd}(\text{OAc})_2$ (20% mol), phosphine (40% mol), additive 2 equiv each, DMF saturated O_2 , conc 0.07 M, 80 °C. ^bDegassed solvent, deoxygenated condition. ^c1 equiv of additive. ^dNot determined.

This suggested oxidation as a key step in the reaction pathway with O_2 or water acting as the source of oxygen. When oxygen was passed through the reaction mixture the yield increased to 14% (entry 3). There are only few examples for arylation of alcohols *via* β -carbon elimination. Miura et al. found that certain α,α -disubstituted arylmethanols react with aryl bromides to give biaryls *via* cleavage of the $\text{sp}^2\text{--sp}^3$ C–C bond in the presence of $\text{Pd}(\text{OAc})_2$ and PPh_3 .²⁰ The role of phosphines in coupling reactions is to stabilize the Pd(0) state and tune the reactivity of palladium;²¹ therefore when PPh_3 was incorporated into the studied reaction the yield further increased to 32% (entry 4). Additionally, in palladium-catalyzed

reactions ligands play a crucial role in determining rates of various steps by controlling the detailed coordination environment at palladium.²¹ Thus, various phosphines were examined, but yields decreased in all cases (entries 7–9). Subsequently, the effects of different solvents were investigated focusing on those that absorb oxygen well (Table 3).

Table 3. Solvent Screening^a

entry	solvent	time [h]	yield of 2a [%]
1	DMSO	3	29
2	DMAc ^b	72	21
3	MeCN	72	traces
4	DCE ^c	72	n. d. ^d
5	toluene	72	n. d. ^d
6	NMP	60	23
7	THF	24	n. d. ^d

^aReaction condition: (CN)₂Cby(III)(OMe)₇ **1a** (14 μmol), Pd(OAc)₂ 20% mol, PPh₃ 40% mol, H₂O 1 equiv, solvent saturated O₂, conc 0.07 M, 80 °C. ^bDimethylacetamide. ^c1,2-Dichloroethane. ^dNot detected.

However, only the reaction in DMSO was comparable with the reaction rate in DMF (entry 1), even though the solubility of oxygen in DMSO has half the capacity of DMF.²² Further optimizations regarding the choice of catalyst and oxidants did not give any significant improvement (see Supporting Information).

The replacement of methyl ester group with *n*-butyl at the *c*-position did not suppress *c*-lactone formation (Table 4, entry

Table 4. Cobryketones^a

entry	R ¹	R ²	time [h]	yield of ketone [%]	yield of <i>c</i> -lactone [%]
1	Me	OMe	4.5	32	40
2	<i>n</i> -Bu	O- <i>n</i> -Bu	24	21	13
3	<i>n</i> -Bu	O- <i>n</i> -Bu	48	14	17
4	Me	N- <i>n</i> -Bu	48	n. d. ^b /c. m. ^c	n. d. ^b /c. m. ^c


^aReaction condition: cobyrinate (14 μmol), Pd(OAc)₂ (20% mol), PPh₃ (40% mol), H₂O (1 equiv), DMF saturated O₂, conc 0.07 M, 80 °C. ^bNot detected. ^cComplicated mixture.

2). The reaction of hepta-*n*-butyl cobyrinate, though much slower, gave a mixture of cobryketone **2b** and *c*-lactone **3b** with yields remaining at the same level. To suppress lactone formation process, *c*-monoamide **1c** was used as a starting material. Unfortunately, the reaction resulted in a complicated mixture of products with no evidence of the desired compound found.

Examples of vitamin B₁₂ lacking one or more of the peripheral side chains especially at β positions are scarce. To the best of our knowledge the only synthetically useful example came from Kräutler's laboratory.²³ Reduction of pyrocobester with Zn in acetic acid gave hexamethyl cobyrinate lacking the *c*-side chain. In our case, by removing the ketone moiety present at the C8 position using a similar reduction method *c*-acid **4** devoid of the *d*-side chain was isolated in a high yield of 81%. Direct esterification of compound **4** gave hexamethyl 8-*nor*-cobyrinate **5a** in 65% yield (Scheme 2). Also the reaction of acid **4** with various amines proceeded smoothly furnishing desired *c*-amides **5b–d** in excellent yields.

Structure Elucidation. The ESI-MS of cobryketone **2a** displayed no molecular ion peaks; instead [M – CN]⁺

Scheme 2. Synthesis of *c*-Acid **4 from Cobryketone **2a****



C₄₉H₆₅CoN₅O₁₃ (*m/z* = 990.39) and [M + Na]⁺ C₄₉H₆₅CoN₅O₁₃ (*m/z* = 1039.38) were observed, which is common for hydrophobic cobalamines. The MS analysis clearly showed a decrease in the molecular mass from [M – CN]⁺ *m/z* = 1062.44 for compound **1a** to [M – CN]⁺ *m/z* = 990.39 for cobryketone **2a** suggesting the loss of C₄H₈O (72.05), which related to the cleavage of one of the methyl propionate moiety and the addition of the oxygen atom. The absorption spectrum of cobryketone **2a** varies from most of known corrinoids except Inhoffen's blue vitamin B₁₂ derivative,¹⁴ suggesting the expansion of conjugation of the double bond system on the corrin ring (Figure 2).




Figure 2. Overlapped UV-vis spectra of heptamethyl cobyrinate **1a**, cobryketone **2a**, and hexamethyl cobyrinate **5a** (35 μM solution) in DCM.

The comparison of absorption spectra showed that the replacement of the propionate side chain with C=O caused a stepwise bathochromic shift of all bands as a consequence of the expansion of the existing conjugated system (Table 5).

However, this was expected as a very pronounced color change could be seen in the isolated compound. The biggest differences were for β and α bands with Δ of ~80 nm, while the γ band was only slightly affected (entries 1, 2). The intensity of

Table 5. Comparison of the Effect of Core Modification on Absorption Spectra^a

entry	compound	λ [nm]			
		ϵ	γ	β	α
1	1a	315	371	549	589
2	2a	324	380	623	673
3	5a	311	370	547	584

^aSpectra recorded in DCM.

all bands decreased and the ratio of intensity of the β band relatively to the α band increased from 0.77 to 1.00 suggesting a change in the vibronic structure of the corrinoid. On the other hand the removal of the *d*-propionate side chain had little effect on the absorption spectra (entry 3).

The complete assignment of signals in ¹H and ¹³C NMR spectra was based on two-dimensional NMR techniques (COSY, HSQC, and HMBC, Figure 3).




Figure 3. Numbering scheme for cobyrketone 2a.

Surprisingly, the perturbation to the B corrin ring has a substantial effect in almost all proton resonances and direct comparison with heptamethyl cobyrinate 1a was impossible (see Figure 4).

The assignment started from the B-ring where the ketone group was located as the remaining part of the compound was unmodified. One of the main features of this spectrum was the presence of the *meso*-proton resonance at 6.41 ppm, indicating that no modification had occurred at this position, and the lack of signals corresponding to C8 H. The second important aspect was the presence of only six singlets corresponding to six $-\text{CO}_2\text{CH}_3$ groups, whereas for heptamethyl cobyrinate 1a seven resonances are present, confirming the loss of one methylester group (see Figure 4).

In ¹³C spectrum an unusually downfield signal at 200.8 ppm was present, which is characteristic of the resonance of the carbonyl group. Subsequently, in the ¹H-detected heteronuclear multiple-bond multiple-quantum coherence (HMBC) experiment the carbonyl peak (200.8 ppm) correlated with four proton signals: 6.41 ppm (C10), 3.10 and 2.75 ppm (both C39; CH_2 -*c*-position), and 0.94 ppm (C38; $-\text{CH}_3$) supporting the loss of *d*-propionate side chain. Following the trail, C10 H (6.41 ppm) correlated to C8 (200.84 ppm), C11 (178.62 ppm), C9 (152.3 ppm), and C12 (47.6 ppm). C39 (CH_2 -*c*-position) correlated to C40 ($\text{C}=\text{O}$, 168.8 ppm), which in turn correlated to C43 ($-\text{CH}_3$, 53.3 ppm) on the methylester. This therefore proves the state of the B-ring. A detailed correlation




Figure 4. Comparison of ¹H NMR spectra of compounds 1a, 2a, and 5a.


table for cobyrketone 2 can be found in the Supporting Information.

The full assignment of heptamethyl cobyrinate 1a was undertaken by Battersby et al., and we compared it to the spectra of hexamethyl cobyrinate 5a (see Figure 4).²⁴ The loss of the *d*-side chain caused substantial changes to the ¹H NMR spectra of ester 5a. As expected only six well resolved signals corresponding to methyl esters were present. Moreover, the resonances of C10 H and C8 H were upfield shifted. In the HMBC experiment the signal at 5.33 ppm (C10 H) cross-peaked with four carbon signals corresponding to C12 (46.5 ppm), C11 (176.4 ppm), C9 (168.5 ppm) and C8 (49.6 ppm). Subsequently, in the ¹H-detected heteronuclear single-bond multiple-quantum coherence (HSQC) experiment the signal relating to C8 (49.6 ppm) correlated with two doublets at 3.38 and 2.56 ppm. These two signals were coupled to each other with geminal coupling constant confirming the 8-position as CH_2 . Furthermore, the correct assignment was supported by the presence of crosspeaks of C10 H (5.33 ppm), C39 H (2.46 and 2.40 ppm), and C38 H (1.14 ppm) with C8 at 49.6 ppm. For a correlation table see Supporting Information.

Mechanistic Considerations. The main byproduct formed in the studied reaction is *c*-lactone 3a, which proved not to transform into cobyrketone 2a; hence the unwanted byproduct is generated competitively to desired ketone 2a. Thus, we assume that the first step requires oxidation at the C8 position to alcohol A (Scheme 3). Such unusual hydroxylation at this position in cobyrinic acid derivatives has been already observed in the synthesis of cobinamides *via* the aminolysis of esters.²⁵

Miura et al. have found that alcoholic substrates can undergo aryl-aryl coupling *via* C-C bond cleavage and that alcoholic oxygen can act as an effective coordinating group.²⁰ Although such types of reactions are most common in strained four-membered ring systems,²⁶ they can also proceed with the liberation of ketones for acyclic alcohols. For example, the reaction of 2-naphthyl-2-propanol with bromobenzene in the

Scheme 3. Mechanistic Hypothesis



presence of $\text{Pd}(\text{OAc})_2/\text{PPh}_3/\text{Cs}_2\text{CO}_3$ furnishes 2-phenyl-naphthalene in 94% yield with the liberation of acetone.¹⁹

In our case the initially formed alcohol can undergo either lactonization to *c*-lactone **3a** or C–C bond cleavage leading to cobryketone **2a**. These may imply C–C bond cleavage proceeding *via* coordination of the alcoholic oxygen to $\text{Pd}(\text{OAc})_2$ followed by selective elimination (Scheme 3). In such type of reactions coordination of the phenolic oxygen to phenylpalladium(II) species is the key step.^{19,20} If an analogous mechanism operates in our reaction, cobryketone formed must be accompanied by some kind of methyl propionate derivative. GC–MS of the crude reaction mixture revealed the presence of a compound with $m/z = 103$. Its fragmentation pattern is in agreement with the database spectra recorded for methyl 3-hydroxypropanoate (see Supporting Information).²⁷ Consequently, it was added as an internal standard supporting its formation during the reaction of heptamethyl cobyrinate with palladium acetate. For hepta-*n*-butyl cobyrinate **1b** GC–MS analysis showed the presence of 3-butoxypropanoic acid instead of *n*-butyl 3-hydroxypropanoate. However, addition of an internal standard revealed that isomerization of the *n*-butyl 3-hydroxypropanoate to 3-butoxypropanoic acid occurred during the GC–MS experiment. To the best of our knowledge the palladium catalyzed C–C bond cleavage providing ketones has only been observed during aryl–aryl coupling.^{19,20} However, in our case, the addition of bromobenzene and Cs_2CO_3 as a base to the reaction mixture did not result in the arylation of the corrin macrocycle. The role of water in the reaction is still unknown. Experiments with isotope labeled H_2O^{17} showed no incorporation of O^{17} into neither *c*-lactone nor cobryketone. The GC–MS of crude reaction also showed no differences in the fragmentation pattern of methyl 3-hydroxypropanoate.

Other possible mechanisms that can be considered involve oxidation of the C8 position to afford hydroperoxide. Upon cleavage of the C–C bond ketone and alcohol are formed.²⁸ Such cumene rearranged type reaction involves radicals as intermediates. To figure out whether the radical intermediate was involved in the reaction, the inhibition experiment with the addition of TEMPO as a trap for the radical²⁹ was performed. Desired cobryketone **2a** was obtained in the same yield as the

initial experiment, ruling out any radical type mechanism (see Supporting Information).

CONCLUSIONS

In conclusion, blue-green cobryketone **2a** was synthesized from heptamethyl cobyrinate **1a** *via* a rare palladium-catalyzed carbon–carbon bond cleavage. We assume that in the first step introduction of the hydroxyl group at the C8 position occurred followed by C–C bond cleavage proceeding *via* coordination of the alcoholic oxygen to $\text{Pd}(\text{OAc})_2$. Subsequent selective elimination furnishes desired ketone. The comparison of absorption spectra of cobryketone **2a** with corrinoid **1a** showed that the replacement of the propionate side chain with $\text{C}=\text{O}$ caused a stepwise bathochromic shift of all bands to longer wavelengths as a result of the expansion of the vitamin's conjugate system of double bonds.

The reduction of cobryketone **2a** with Zn led to hexamethyl cobyrinate **5a** in excellent yield. This new derivative represent a rare example of vitamin B₁₂ related corrinoids that lack one or more peripheral side chain.

EXPERIMENTAL SECTION

General information. Analytical grade solvents were used as received. ^1H and ^{13}C NMR spectra were recorded at room temperature with TMS as an internal standard or calibrated on the solvent residual peak (C_6D_6 , 7.15 ppm; toluene-*d*₈, 2.08 ppm). Multiplicities are indicated by s (singlet), d (doublet), t (triplet), td (triplet of doublets), qdd (quartet of double of doublets), and m (multiplet). Coupling constants, *J*, are reported in hertz. Dry column vacuum chromatography (DCVC)³⁰ was performed using silica gel GF₂₅₄ (10–40 μm). Thin layer chromatography (TLC) was performed using silica gel GF₂₅₄, 0.20 mm thickness. Low and high resolution mass spectra were recorded using electrospray ionization (ESI) method and time of flight (TOF) detector. UV–vis absorption spectra were recorded in DCM unless otherwise noted. Melting points are uncorrected. $(\text{CN})_2\text{Cby}(\text{III})(\text{OMe})_7$ **1a**,³¹ $(\text{CN})_2\text{Cby}(\text{III})(\text{O}-n\text{-Bu})_7$ **1b**,^{8a} and monoamide **1c**^{10b} were synthesized according to the literature procedures.

$(\text{CN})_2\text{Cby}(\text{III})(8\text{-CO})(\text{OMe})_6$ (2a**).** Dry DMF was saturated with oxygen by passing it through for 1 h at room temperature. Palladium(II) acetate (0.6 mg, 2.8 μmol), triphenylphosphine (1.4 mg, 5.5 μmol), and heptamethyl cobyrinate **1a** (15 mg, 14 μmol) were weighed into a screw cap Schlenk tube. A H_2O in DMF (0.2 mL; 0.07 M) solution was prepared and added to the reaction mixture. A balloon of oxygen was attached, and the mixture was stirred at 80 °C in darkness for 4.5 h. The mixture was then diluted with DCM (20 mL) and washed with NaCN aq (20 mL). The product was extracted using DCM. The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated *in vacuo*. The crude product was purified using DCVC, 1–3% MeOH in toluene. Recrystallization from hexane/toluene gave cobryketone **2a** as a blue-green solid (4.5 mg, 32%): mp 140–142 °C. *R*_f 0.41 (15% MeOH in toluene); ^1H NMR (500 MHz, C_6D_6 , 303 K) δ 6.41 (s, 1H), 4.00 (d, *J* = 10.4 Hz, 1H), 3.63 (d, *J* = 8.1 Hz, 1H), 3.55 (s, 3H), 3.43 (s, 3H), 3.36 (s, 3H), 3.33 (s, 3H), 3.29 (s, 3H), 3.19 (s, 3H), 3.10 (d, *J* = 16.2 Hz, 1H), 2.92–2.83 (m, 2H), 2.82 (t, *J* = 6.0 Hz, 1H), 2.75 (d, *J* = 16.2 Hz, 1H), 2.76–2.68 (m, 1H), 2.60–2.50 (m, 2H), 2.49–2.34 (m, 3H), 2.33–2.12 (m, 4H), 2.21 (s, 3H), 2.11–1.95 (m, 2H), 2.03 (s, 3H), 1.91–1.68 (m, 3H), 1.45 (s, 3H), 1.15 (s, 3H), 0.94 (s, 3H), 0.92 (s, 6H), 0.89 (s, 3H); ^{13}C NMR (125 MHz, C_6D_6 , 303 K) δ 200.8, 178.6, 176.2, 174.0, 173.6, 172.7, 172.2, 171.9, 171.7, 168.8, 163.7, 157.2, 152.3, 105.9, 105.6, 87.6, 83.4, 76.0, 58.7, 57.6, 54.2, 53.3, 51.7, 51.5, 51.3, 51.2, 51.0, 50.4, 47.6, 46.7, 42.2, 41.1, 39.8, 34.3, 33.4, 31.7, 30.7, 30.0, 29.9, 25.9, 24.9, 23.0, 21.5, 19.3, 18.6, 16.6, 16.0, 14.9 ppm; HRMS ESI (*m/z*) calcd for $\text{C}_{49}\text{H}_{65}\text{CoN}_5\text{O}_{13}$ [$\text{M} - \text{CN}$]⁺ 990.3905, found 990.3914; UV–vis (CH_2Cl_2) λ (ϵ , $\text{M}^{-1}\text{cm}^{-1}$) 305 (5.63×10^3), 324 (5.30×10^3), 380 (2.13×10^4), 436 (3.53×10^3), 461 (3.63×10^3), 623 (7.94×10^3),

673 (7.93 × 10³). Anal. Calcd for C₅₀H₆₅CoN₆O₁₃: C 59.05, H 6.44, N 8.26. Found: C 58.89, H 6.55, N 8.04.

(CN)₂Cby(III)(8-CO)(O-*n*-Bu)₆ (2b). Following the procedure described for the synthesis of ketone **2a**, compound **2b** was obtained from hepta-*n*-butyl cobyrate (**1b**) (77 mg, 5.5 μmol), palladium(II) acetate (5.5 mg, 11 μmol), and triphenylphosphine (5.8 mg, 22 μmol). The reaction was stirred with a continuous stream of O₂ passing through the solution for 24 h. The crude product was purified using DCVC, 0.5–3% *i*-PrOH in DCM. Ketone **2b** was obtained as a blue-green solid (14.5 mg, 21%): mp 114–117 °C. *R*_f 0.41 (15% *i*-PrOH in hexane); ¹H NMR (500 MHz, C₆D₆, 303 K) δ 6.40 (s, 1H), 4.22 (m, 2H), 4.14–3.93 (m, 10H), 3.93–3.86 (m, 3H), 3.10 (d, *J* = 15.9 Hz, 1H), 3.02–2.93 (m, 2H), 2.89–2.80 (m, 2H), 2.76 (d, *J* = 15.9 Hz, 1H), 2.71–2.44 (m, 5H), 2.41–2.25 (m, 3H), 2.31 (s, 3H), 2.24–1.97 (m, 5H), 2.13 (s, 3H), 1.96–1.88 (m, 1H), 1.82–1.72 (m, 1H), 1.52 (s, 3H), 1.50–1.31 (m, 16H), 1.30 (s, 3H), 1.28–1.12 (m, 15H), 0.91 (s, 3H), 0.85–0.72 (m, 18H) ppm; ¹³C NMR (125 MHz, C₆D₆, 303 K) δ 200.8, 178.5, 176.3, 174.1, 173.3, 172.4, 172.0, 171.7, 171.4, 168.3, 163.8, 157.3, 152.5, 105.8, 105.7, 87.6, 83.5, 76.1, 66.0, 65.1, 64.8, 64.7, 64.6, 64.2, 58.8, 57.7, 54.2, 50.4, 47.5, 46.7, 42.5, 41.3, 39.8, 34.5, 33.6, 32.0, 31.03, 30.95, 30.92, 30.89, 30.74, 30.72, 30.69, 30.3, 30.2, 30.1, 25.9, 25.0, 23.0, 21.4, 19.5, 19.42, 19.37, 19.34, 19.1, 18.7, 16.7, 15.8, 14.9, 13.9, 13.79, 13.78, 13.73, 13.70 ppm; HRMS ESI (*m/z*) calcd for C₆₇H₁₀₁CoN₅O₁₃ [M – CN]⁺ 1242.6728, found 1242.6771; UV–vis (CH₂Cl₂) λ (ε, M⁻¹ cm⁻¹) 305 (6.82 × 10³), 380 (2.57 × 10⁴), 434 (4.30 × 10³), 460 (4.21 × 10³), 623 (9.91 × 10³), 673 (1.01 × 10⁴). Anal. Calcd for C₆₈H₁₀₁CoN₆O₁₃ + H₂O: C 63.43, H 8.06, N 6.53. Found: C 63.27, H 8.01, N 6.30.

(CN)₂Cby(III)(c-lactone)(O-*n*-Bu)₆ (3b). Following the procedure described for the synthesis of ketone **2a** compound **3b** was obtained from hepta-*n*-butyl cobyrate **1b** (77 mg, 5.5 μmol), palladium(II) acetate (5.5 mg, 11 μmol), and triphenylphosphine (5.8 mg, 22 μmol). The reaction was stirred with a continuous stream of O₂ passing through the solution for 24 h. The crude product was purified using DCVC, 0.5–5% *i*-PrOH in DCM. Lactone **3b** was obtained as a purple solid (9 mg, 13%): mp 98–102 °C. *R*_f 0.32 (15% *i*-PrOH in hexane); ¹H NMR (500 MHz, C₆D₆, 303 K) δ 5.87 (s, 1H), 4.15–3.86 (m, 14H), 3.02 (d, *J* = 15.0 Hz, 1H), 2.94 (m, 1H), 2.83–2.63 (m, 4H), 2.62–2.34 (m, 8H), 2.32–2.23 (m, 3H), 2.25 (s, 3H), 2.20–1.93 (m, 5H), 1.96 (s, 3H), 1.87 (m, 1H), 1.78 (m, 1H), 1.52–1.06 (m, 30H), 0.98 (s, 3H), 0.96 (s, 3H), 0.92 (s, 3H), 0.84–0.75 (m, 15H), 0.73 (t, *J* = 7.3 Hz, 3H), 0.68 (t, *J* = 7.4 Hz, 3H) ppm; ¹³C NMR (125 MHz, C₆D₆, 303 K) δ 178.7, 176.1, 175.4, 173.3, 172.4, 172.2, 171.93, 171.89, 171.7, 171.4, 166.0, 163.6, 160.6, 104.2, 103.8, 93.7, 89.1, 83.1, 75.5, 65.1, 64.9, 64.64, 64.59, 64.57, 64.1, 58.6, 57.2, 54.1, 50.7, 47.5, 46.2, 42.2, 41.9, 39.8, 33.9, 33.3, 32.0, 31.04, 30.99, 30.91, 30.85, 30.73, 30.71, 30.4, 30.2, 29.2, 26.0, 25.0, 22.3, 19.43, 19.37, 19.36, 19.33, 19.33, 19.29, 18.9, 18.2, 17.04, 17.02, 15.7, 13.82, 13.80, 13.78, 13.74, 13.65 ppm; HRMS ESI (*m/z*) calcd for C₇₀H₁₀₅CoN₅O₁₄ [M – CN]⁺ 1298.6990, found 1298.7003; UV–vis (CH₂Cl₂) λ (ε, M⁻¹ cm⁻¹) 279 (1.06 × 10³), 319 (9.50 × 10³), 370 (2.65 × 10⁴), 422 (2.80 × 10³), 577 (9.03 × 10³), 595 (1.03 × 10⁴). Anal. Calcd for C₇₁H₁₀₅CoN₆O₁₄ + H₂O: C 63.47, H 8.03, N 6.25. Found: C 63.63, H 7.95, N 6.16.

(CN)₂-8-*nor*-Cby(III)(c-acid)(OMe)₅ (4). Compound **2** (61 mg, 60 μmol) was dissolved in toluene (4 mL) and AcOH (0.8 mL). The mixture was degassed by sonicating and bubbling argon for 2 min. It was then vigorously stirred, and freshly activated zinc dust (930 mg, 14.2 mmol) was added. The reaction was left at room temperature in darkness for 30 min. It was then passed through Celite and washed with DCM until the Celite remained colorless. The filtrate was then neutralized with NaHCO₃ aq and washed with NaCN aq, and organic layer was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The crude product was purified using DCVC, 2–25% MeOH in toluene. Recrystallization from hexane/DCM gave acid **4** as a red solid (48 mg, 81%) and was used without further purification: *R*_f 0.46 (25% MeOH in toluene); HRMS ESI (*m/z*) calcd for C₄₈H₆₅CoN₅O₁₂ [M – CN]⁺ 962.3962, found 962.3951.

The broadening of peaks in the ¹H NMR spectrum made it impossible to decipher, and consequently high resolution ¹³C spectra

could not be obtained. This was caused by the presence of the acid group.

(CN)₂-8-*nor*-Cby(III)(OMe)₆ (5a). *c*-Acid **4** (29 mg, 29 μmol), EDC-HCl (14 mg, 88 μmol), and DMAP (11 mg, 88 μmol) were dissolved in dry DCM (3 mL) and cooled in an ice bath. The mixture was then treated with methanol (0.5 mL, 12 mmol) under an argon atmosphere in darkness and allowed to stir at room temperature for 16 h, after which the reaction mixture was diluted with DCM (25 mL) and washed with NaCN aq (25 mL). The organic layer was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The crude product was purified using DCVC, 0.5–4% MeOH in toluene. Recrystallization from hexane/toluene gave compound **5a** as a purple solid (10 mg, 65%): mp 178–182 °C. *R*_f 0.37 (5% MeOH in toluene); ¹H NMR (500 MHz, C₆D₆, 303 K) δ 5.33 (s, 1H), 3.98 (d, *J* = 10.5 Hz, 1H), 3.75 (d, *J* = 7.7 Hz, 1H), 3.41 (s, 3H), 3.38 (d, *J* = 17.7 Hz, 1H), 3.364 (s, 3H), 3.362 (s, 3H), 3.34 (s, 3H), 3.30 (s, 3H), 3.21 (s, 3H), 2.94 (d, *J* = 15.3 Hz, 1H), 2.85 (td, *J* = 10.1 and 3.1 Hz, 1H), 2.78 (t, *J* = 5.6 Hz, 1H), 2.77–2.68 (m, 2H), 2.56 (d, *J* = 17.7 Hz, 1H), 2.53–2.30 (m, 8H), 2.24 (d, *J* = 15.3 Hz, 1H), 2.20 (s, 3H), 2.22–2.09 (m, 2H), 2.02 (s, 3H), 2.08–1.97 (m, 1H), 1.96–1.74 (m, 3H), 1.49 (s, 3H), 1.15 (s, 3H), 1.14 (s, 3H), 0.99 (s, 3H), 0.96 (s, 3H), 0.95 (s, 3H) ppm; ¹³C NMR (125 MHz, C₆D₆, 303 K) δ 176.4, 175.4, 174.7, 173.8, 172.9, 172.3, 172.1, 171.7, 170.5, 168.5, 164.7, 163.9, 103.7, 102.3, 89.9, 82.9, 75.4, 58.4, 57.4, 53.8, 51.7, 51.5, 51.4, 51.3, 51.2, 51.0, 49.6, 46.7, 46.3, 44.8, 42.2, 41.4, 39.8, 34.2, 33.3, 31.9, 30.9, 30.7, 30.0, 26.0, 24.9, 24.7, 22.5, 19.6, 18.4, 16.8, 15.5, 15.4 ppm; HRMS ESI (*m/z*) calcd for C₅₀H₆₇CoN₆O₁₂ [M]⁺ 1002.4149, found 1002.4133; UV–vis (CH₂Cl₂) λ (ε, M⁻¹ cm⁻¹) 277 (8.21 × 10³), 311 (8.52 × 10³), 370 (2.54 × 10⁴), 417 (2.46 × 10³), 546 (8.52 × 10³), 584 (8.75 × 10³). Anal. Calcd for C₅₀H₆₇CoN₆O₁₂ + H₂O: C 58.82, H 6.81, N 8.23. Found: C 58.97, H 6.84, N 8.02.

(CN)₂-8-*nor*-Cby(III)(c-2-propylamide)(OMe)₅ (5b). Compound **4** (30 mg, 30 μmol), isopropylamine (11 μL, 135 μmol), and DIPEA (12 μL, 70 μmol) were dissolved in dry DMF (2 mL) under an argon atmosphere in darkness. DEPC (22 μL, 145 μmol) was then added, and the mixture stirred at room temperature for 16 h, after which it was diluted with DCM (25 mL) and washed with NaCN aq (25 mL). The organic layer was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The crude product was purified using DCVC, 0.5–2.5% MeOH in DCM. Recrystallization from hexane/toluene gave compound **5b** as a purple solid (26 mg, 82%): mp 149–151 °C. *R*_f 0.35 (15% MeOH in toluene); ¹H NMR (500 MHz, toluene-*d*₈, 303 K) δ 7.04–6.93 (m, 1H), 5.31 (s, 1H), 4.15 (dq, *J* = 13.5 and 6.7 Hz, 1H), 3.84 (m, 1H), 3.74 (d, *J* = 10.6 Hz, 1H), 3.43 (s, 3H), 3.40 (s, 3H), 3.38 (s, 3H), 3.34 (s, 3H), 3.31 (s, 3H), 2.83–2.76 (m, 2H), 2.73 (d, *J* = 15.4 Hz, 1H), 2.70–2.18 (m, 13H), 2.16 (s, 6H), 2.14–2.06 (m, 1H), 2.02–1.90 (m, 3H), 1.81–1.64 (m, 2H), 1.60 (s, 3H), 1.45 (s, 3H), 1.15 (s, 3H), 1.05 (d, *J* = 2.2 Hz, 3H), 1.04 (d, *J* = 2.2 Hz, 3H), 1.03 (s, 3H), 0.94 (s, 3H), 0.89 (s, 3H) ppm; ¹³C NMR (125 MHz, toluene-*d*₈, 303 K) δ 176.0, 175.5, 175.3, 173.8, 172.8, 172.3, 171.8, 171.6, 168.6, 163.8, 163.6, 106.1, 102.1, 90.4, 83.1, 75.1, 58.5, 57.4, 53.8, 52.4, 51.7, 51.4, 51.3, 51.2, 51.0, 48.0, 46.5, 46.1, 46.0, 41.6, 41.5, 39.8, 33.8, 32.9, 31.9, 31.5, 30.6, 29.8, 25.8, 24.9, 23.2, 22.7, 22.6, 22.4, 19.5, 18.0, 16.9, 16.1, 15.6 ppm; HRMS ESI (*m/z*) calcd for C₅₂H₇₂CoN₇O₁₁Na [M + Na]⁺ 1052.4520, found 1052.4518; UV–vis (CH₂Cl₂) λ (ε, M⁻¹ cm⁻¹) 278 (1.06 × 10⁴), 312 (9.13 × 10³), 371 (2.60 × 10⁴), 422 (2.48 × 10³), 547 (8.26 × 10³), 587 (1.01 × 10⁴). Anal. Calcd for C₅₂H₇₂CoN₇O₁₁ + 2H₂O: C 58.58, H 7.19, N 9.20. Found: C 58.75, H 7.22, N 9.17.

(CN)₂-8-*nor*-Cby(III)(c-2-hydroxyethylamide)(OMe)₅ (5c). Following the procedure of compound **5b**, compound **5c** was synthesized using ethanoloamine (8 μL, 135 μmol) instead of isopropylamine. The crude product was purified using DCVC, 1–5% EtOH in DCM. Recrystallization from hexane/toluene gave compound **5c** as a purple solid (28 mg, 90%): mp 138–142 °C. *R*_f 0.45 (20% MeOH in toluene); ¹H NMR (500 MHz, toluene-*d*₈, 303 K) δ 7.05–7.00 (m, 1H), 5.30 (s, 1H), 4.00 (t, *J* = 6.5 Hz, 1H), 3.91 (m, 1H), 3.69 (d, *J* = 10.6 Hz, 1H), 3.53 (m, 2H), 3.43 (s, 3H), 3.41–3.37 (m, 2H), 3.40 (s, 3H), 3.39 (s, 3H), 3.38 (s, 3H), 3.35 (s, 3H), 2.83–2.76 (m, 3H), 2.67 (m, 1H), 2.58 (m, 1H), 2.48 (d, *J* = 15.9 Hz, 1H), 2.45–2.32 (m, 5H), 2.31–2.20 (m, 2H), 2.20–2.11 (m, 3H), 2.17 (s, 3H), 2.15 (s, 3H),

2.03–1.86 (m, 4H), 1.76 (m, 1H), 1.67 (m, 1H), 1.51 (s, 3H), 1.45 (s, 3H), 1.16 (s, 3H), 1.04 (s, 3H), 0.96 (s, 3H), 0.85 (s, 3H) ppm; ^{13}C NMR (125 MHz, toluene- d_6 , 303 K) δ 176.2, 175.8, 175.7, 173.7, 172.7, 172.2, 171.9, 171.6, 169.6, 168.4, 163.7, 162.7, 106.9, 102.3, 90.3, 83.0, 75.1, 61.9, 58.5, 57.0, 53.8, 52.4, 51.7, 51.3, 51.2, 51.0, 48.0, 46.7, 46.5, 46.4, 43.8, 41.7, 39.7, 33.9, 32.8, 31.7, 31.5, 30.5, 29.8, 25.7, 24.9, 23.6, 22.4, 19.5, 17.9, 17.0, 15.7, 15.6 ppm; HRMS ESI (m/z) calcd for $\text{C}_{51}\text{H}_{70}\text{CoN}_7\text{O}_{12}\text{Na} [\text{M} + \text{Na}]^+$ 1054.4312, found 1054.4303; UV-vis (CH_2Cl_2) λ (ϵ , $\text{M}^{-1} \text{cm}^{-1}$) = 278 (1.09×10^4), 311 (9.18×10^3), 370 (2.71×10^4), 420 (2.49×10^3), 547 (8.68×10^3), 586 (9.52×10^3). Anal. Calcd for $\text{C}_{51}\text{H}_{70}\text{CoN}_7\text{O}_{12} + 2\text{H}_2\text{O}$: C 57.35, H 6.98, N 9.18. Found: C 57.38, H 6.77, N 9.17.

(CN) $_2$ -8-nor-Cby(III)(c-propargylamide)(OMe) $_5$ (5d). Following the procedure of compound 5b, compound 5d was synthesized using acid 4 (10 mg, 10 μmol), propargylamine (2.9 μL , 45 μmol) instead of isopropylamine, DIPEA (4 μL , 23 μmol), DEPC (7.3 μL , 48 μmol), and dry DMF (0.7 mL). The crude product was purified using DCVC, 0.5–2.5% MeOH in DCM. Recrystallization from hexane/toluene gave compound 5d as a purple solid (8.3 mg, 80%): mp 145–147 °C. R_f 0.40 (15% MeOH in toluene); ^1H NMR (500 MHz, toluene- d_6 , 303 K) δ 7.39 (t, $J = 5.4$ Hz, 1H), 5.30 (s, 1H), 3.95 (qdd, $J = 17.3$ and 5.4 and 2.4 Hz, 2H), 3.74 (t, $J = 9.4$ Hz, 2H), 3.43 (s, 3H), 3.40 (s, 3H), 3.39 (s, 3H), 3.34 (s, 3H), 3.34 (s, 3H), 2.84–2.77 (m, 2H), 2.73–2.53 (m, 4H), 2.53–2.32 (m, 7H), 2.32–2.14 (m, 4H), 2.18 (s, 3H), 2.11 (s, 3H), 2.02–1.93 (m, 2H), 1.93–1.84 (m, 2H), 1.81–1.66 (m, 2H), 1.52 (s, 3H), 1.44 (s, 3H), 1.16 (s, 3H), 1.04 (s, 3H), 0.95 (s, 3H), 0.94 (s, 3H) ppm; ^{13}C NMR (125 MHz, toluene- d_6 , 303 K) δ 178.7, 178.1, 177.9, 176.2, 175.2, 174.8, 174.5, 174.1, 171.7, 170.9, 166.3, 165.8, 108.6, 104.7, 92.8, 85.5, 83.5, 77.6, 73.1, 61.1, 59.9, 56.3, 54.2, 54.1, 53.9, 53.8, 53.5, 50.0, 49.1, 48.8, 47.8, 44.3, 42.2, 36.3, 35.5, 34.4, 33.8, 33.1, 32.3, 31.3, 28.3, 27.3, 26.1, 24.9, 22.0, 20.6, 19.4, 18.4, 18.1 ppm; HRMS ESI (m/z) calcd for $\text{C}_{52}\text{H}_{68}\text{CoN}_7\text{O}_{11}\text{Na} [\text{M} + \text{Na}]^+$ 1048.4207, found 1048.4200; UV-vis (CH_2Cl_2) λ (ϵ , $\text{M}^{-1} \text{cm}^{-1}$) 278 (8.84×10^3), 312 (7.42×10^3), 371 (2.18×10^4), 421 (2.07×10^3), 547 (6.86×10^3), 587 (8.41×10^3). Anal. Calcd for $\text{C}_{52}\text{H}_{68}\text{CoN}_7\text{O}_{11} + \text{H}_2\text{O}$: C 59.82, H 6.76, N 9.39. Found: C 59.80, H 6.73, N 9.17.

■ ASSOCIATED CONTENT

● Supporting Information

All experimental details and complete analytical data for new products including $^1\text{H}/^1\text{H}$ COSY, $^{13}\text{C}/^1\text{H}$ HSQC and $^{13}\text{C}/^1\text{H}$ HMBC NMR spectra and correlation tables for compounds 2a and 5a, GC–MS results. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: dorota.gryko@icho.edu.pl

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was supported by the European Regional Development Fund with the TEAM program, grant no. TEAM/2009-3/4.

■ REFERENCES

(1) (a) Eschenmoser, A. *Pure Appl. Chem.* **1963**, *7*, 297–316. (b) Woodward, R. B. *Pure Appl. Chem.* **1968**, *17*, 519–547. (c) Woodward, R. B. *Pure Appl. Chem.* **1971**, *25*, 283–304. (d) Eschenmoser, A. *Pure Appl. Chem.* **1971**, *15*, 69–106 (Special Lectures XXIII IUPAC Int. Congress, Boston). (e) Woodward, R. B. *Pure Appl. Chem.* **1973**, *33*, 145–178. (f) Eschenmoser, A.; Wintner, C. E. *Science* **1977**, *196*, 1410–1426. (g) Eschenmoser, A. *Naturwissenschaften* **1974**, *61*, 513–525. (h) Woodward, R. B. In *Vitamin B₁₂, Proceedings of the Third European Symposium on Vitamin*

B₁₂ and Intrinsic Factors; Zagalak, B., Friedrich, W., Eds.; Walter de Gruyter: Zürich, 1979; pp 37–88.

(2) (a) Banerjee, R. In *Chemistry and Biochemistry of B-12*; John Wiley and Sons: New York, 1999. (b) Brown, K. L. *Chem. Rev.* **2005**, *105*, 2075–2149. (c) Gruber, K.; Puffer, B.; Kräutler, B. *Chem. Soc. Rev.* **2011**, *40*, 4346–4363.

(3) Broderick, K. E.; Potluri, P.; Zhuang, S.; Scheffler, I. E.; Sharma, V. S.; Pilz, R. B.; Boss, G. R. *Exp. Biol. Med.* **2006**, *641*–649.

(4) (a) Xu, Z.; Chen, X.; Kim, H. N.; Yoon, J. *Chem. Soc. Rev.* **2010**, *39*, 127–137. (b) Blackledge, W. C.; Blackledge, Ch. W.; Griesel, A.; Mahon, S. B.; Brenner, M.; Pilz, R. B.; Boss, G. R. *Anal. Chem.* **2010**, *82*, 4216–4221. (c) Männel-Croisé, C.; Zelder, F. *Anal. Methods* **2012**, *4*, 2632–2634.

(5) (a) Petrus, A. K.; Fairchild, T. J.; Doyle, R. P. *Angew. Chem., Int. Ed.* **2009**, *48*, 1022–1028. (b) Clardy, M. S.; Allis, D. G.; Fairchild, T. J.; Doyle, R. P. *Expert Opin. Drug Deliv.* **2011**, *8*, 127–140. (c) Fazen, Ch. H.; Valentin, D.; Fairchild, T. J.; Doyle, R. P. *J. Med. Chem.* **2011**, *54*, 8707–8711. (d) Clardy-James, S.; Chepurny, O. G.; Leech, C. A.; Holz, G. G.; Doyle, R. P. *Chem. Med. Chem.* **2013**, *8*, 582–586.

(6) (a) Wuerges, J.; Garau, G.; Geremia, S.; Fedosov, S. N.; Pertersen, T. E.; Randaccio, L. *Proc. Natl. Acad. Sci. U.S.A.* **2006**, *103*, 4386–4391. (b) Chalasani, K. B.; Russell-Jones, G. J.; Jain, A. K.; Diwan, P. V.; Jain, S. K. *J. Controlled Release* **2007**, *122*, 141–150. (c) Bagnato, J. D.; Eilers, A. L.; Horton, R. A.; Grissom, Ch. B. *J. Org. Chem.* **2004**, *69*, 8987–8996. (d) Russell-Jones, G. J.; McEwan, J. F. U.S. Patent US006150341A, 2000.

(7) (a) Shimakoshi, H.; Maeyama, Y.; Kaieda, T.; Matsuo, T.; Matsui, E.; Naruta, Y.; Hisaeda, Y. *Bull. Chem. Soc. Jpn.* **2005**, *78*, 859–863. (b) Murakami, Y.; Hisaeda, Y.; Kohno, H.; Ohno, T. *Chem. Lett.* **1992**, 909–912. (c) Hisaeda, Y.; Nishioka, T.; Inoue, Y.; Asada, K.; Hayashi, T. *Coord. Chem. Rev.* **2000**, *198*, 21–37. (d) Hisaeda, Y.; Masuko, T.; Hanashima, E.; Hayashi, T. *Sci. Technol. Adv. Mat.* **2006**, *7*, 655–661.

(8) (a) Murakami, Y.; Hisaeda, Y.; Ohno, T. *Bull. Chem. Soc. Jpn.* **1984**, *57*, 2091–2097. (b) Müller, S.; Wolleb, A.; Walder, L.; Keese, R. *Helv. Chim. Acta* **1990**, *73*, 1659–1668.

(9) (a) Pfammatter, M. J.; Dabre, T.; Keese, R. *Helv. Chim. Acta* **1998**, *81*, 1105–1116. (b) Shimakoshi, H.; Tokunaga, M.; Kuroiwa, K.; Kimizuka, N.; Hisaeda, Y. *Chem. Commun.* **2004**, 50–51. (c) Otten, T.; Darbre, T.; Cosnier, S.; Abrantes, L.; Correia, J.; Keese, R. *Helv. Chim. Acta* **1998**, *81*, 1117–1126. (d) Mayor, M.; Scheffold, R. *Helv. Chim. Acta* **1997**, *80*, 1183–1189.

(10) (a) Proinsias, K. ó; Sessler, J. L.; Kurcoń, S.; Gryko, D. *Org. Lett.* **2010**, *12*, 4674–4677. (b) Proinsias, K. ó; Giedyk, M.; Loska, R.; Chromiński, M.; Gryko, D. *J. Org. Chem.* **2011**, *76*, 6806–6811. (c) Proinsias, K. ó; Gryko, D. T.; Hisaeda, Y.; Martin, E.; Sessler, J. L.; Gryko, D. *J. Med. Chem.* **2012**, *55*, 8943–8947.

(11) Proinsias, K. ó; Kurcoń, S.; Gryko, D. *Eur. J. Org. Chem.* **2012**, 154–159.

(12) Brown, K. L.; Cheng, S.; Zubkowski, J. D.; Valente, E. J. *Inorg. Chem.* **1996**, *35*, 3442–3446.

(13) Fedosov, N. S.; Reutz, M.; Gruber, K.; Fedosova, N. U.; Kräutler, B. *Biochemistry* **2011**, *50*, 8090–8101.

(14) Ernst, L.; Holze, G.; Inhoffen, H. H. *Liebigs Ann. Chem.* **1981**, 198–201.

(15) Dersov, B.; Ernst, L.; Grotjahn, L.; Koppenhagen, V. B. *Angew. Chem., Int. Ed.* **1981**, *20*, 1048–1049.

(16) (a) Grüning, B.; Holze, G.; Jenny, T. A.; Nesvadba, P.; Gossauer, A.; Ernst, L.; Sheldrick, W. S. *Helv. Chim. Acta* **1985**, *68*, 1754–1770. (b) Gossauer, A.; Grüning, B.; Ernst, L.; Becker, W.; Sheldrick, W. S. *Angew. Chem., Int. Ed. Engl.* **1977**, *16*, 481–482. (c) Hinze, R.-P.; Schiebel, H. M.; Laas, H.; Gossauer, K.-P. A.; Inhoffen, H. H. *Liebigs Ann. Chem.* **1979**, 811–828. (d) Kräutler, B. *Helv. Chim. Acta* **1982**, *65*, 1941–1948. (e) Kräutler, B.; Štěpánek, R. *Angew. Chem., Int. Ed. Engl.* **1985**, *24*, 62–64. (f) Grüning, B.; Holze, G.; Gossauer, A. *Helv. Chim. Acta* **1985**, *68*, 1771–1781. (g) Chemyaly, S. M.; Brown, K. L.; Fernandes, M. A.; Munro, O. Q.; Grimmer, C.; Marques, H. M. *Inorg. Chem.* **2011**, *50*, 8700–8718. (h) Schlingmann, G.; Dresov, B.; Koppenhagen, V. B.; Becker, W.; Sheldrick, W. S. *Angew. Chem., Int. Ed. Engl.* **1980**, *19*, 321–322.

(17) (a) Murakami, M.; Matsuda, T. *Chem. Commun.* **2011**, 47, 1100–1105. (b) Satoh, T.; Miura, M. In *Topics in Organometallic Chemistry*; Chatani, N., Ed.; Springer-Verlag: Berlin Heidelberg, 2007; pp 61–84.

(18) Kondo, T.; Kodoi, K.; Nishinaga, E.; Okada, T.; Morisaki, Y.; Watanabe, Y.; Mitsudo, T. *J. Am. Chem. Soc.* **1998**, 120, 5587–5588.

(19) Terao, Y.; Wakui, H.; Nomoto, M.; Satoh, T.; Miura, M.; Nomura, M. *J. Org. Chem.* **2003**, 68, 5236–5243.

(20) Terao, Y.; Wakui, H.; Satoh, T.; Miura, M.; Nomura, M. *J. Am. Chem. Soc.* **2001**, 123, 10407–10408.

(21) (a) Negishi, E.-i.; Takahashi, T.; Akiyoshi, K. *J. Organomet. Chem.* **1987**, 334, 181–194. (b) Fleckenstein, C. A.; Plenio, H. *Chem. Soc. Rev.* **2010**, 39, 694–711. (c) Martin, R.; Buchwald, S. L. *Acc. Chem. Res.* **2008**, 41, 1461–1473. (d) Schilz, M.; Plenio, H. *J. Org. Chem.* **2012**, 77, 2798–2807.

(22) (a) Battino, R.; Rettieh, T. R.; Tominaga, T. *J. Phys. Chem. Ref. Data* **1983**, 12, 163–178. (b) Achord, J. M.; Hussey, C. L. *Anal. Chem.* **1980**, 52, 601–602.

(23) Kräutler, B. *Chem.—Eur. J.* **2012**, 18, 9032–9045.

(24) Battersby, A. R.; Edington, C.; Fookes, Ch. J. R.; Hook, J. M. *J. Chem. Soc., Perkin Trans. 1* **1982**, 2265–2277.

(25) Proinsias, K. ó; Giedyk, M.; Sharina, I. G.; Martin, E.; Gryko, D. *Med. Chem. Lett* **2012**, 3, 476–479.

(26) Seiser, T.; Cramer, N. *Org. Biomol. Chem.* **2009**, 7, 2835–2840.

(27) The NIST Mass Spectral Search Program for the NIST/EPA/NIH Mass Spectral Library for comparison was used. Comparison of experimental and database patterns of methyl 3-hydroxypropanoate available in Supporting Information

(28) Frank, Ch. E. *Chem. Rev.* **1950**, 46, 155–169.

(29) Wu, X.; Chu, L.; Qing, F.-L. *Angew. Chem., Int. Ed.* **2013**, 52, 2198–2202.

(30) Pedersen, D. S.; Rosenbohm, C. *Synthesis* **2001**, 2431–2434.

(31) Werthemann, L. Dissertation, ETH Zürich (no. 4097); Juris Druck and Verlag: Zürich, 1968.